- vaccine: BNT162b2
  dosage: 1.0
  infection: ''
  num_ref_name: 27
  num_fold: 4093
  S: 3167
  I: 742
  R: 184
  median_fold: 2.0
  percent: 2.8
  priority: 1
- vaccine: BNT162b2
  dosage: 1.0
  infection: infected
  num_ref_name: 24
  num_fold: 1273
  S: 891
  I: 346
  R: 36
  median_fold: 3.0
  percent: 0.88
  priority: 1
- vaccine: BNT162b2
  dosage: 2.0
  infection: ''
  num_ref_name: 182
  num_fold: 22302
  S: 15353
  I: 5118
  R: 1831
  median_fold: 2.9
  percent: 15.0
  priority: 1
- vaccine: BNT162b2
  dosage: 2.0
  infection: infected
  num_ref_name: 51
  num_fold: 3697
  S: 2278
  I: 1211
  R: 208
  median_fold: 3.5
  percent: 2.5
  priority: 1
- vaccine: BNT162b2
  dosage: 3.0
  infection: ''
  num_ref_name: 84
  num_fold: 7805
  S: 4151
  I: 2944
  R: 710
  median_fold: 4.3
  percent: 5.4
  priority: 1
- vaccine: BNT162b2
  dosage: 3.0
  infection: infected
  num_ref_name: 23
  num_fold: 2218
  S: 1291
  I: 675
  R: 252
  median_fold: 3.9
  percent: 1.5
  priority: 1
- vaccine: BNT162b2
  dosage: 4.0
  infection: ''
  num_ref_name: 7
  num_fold: 499
  S: 50
  I: 215
  R: 234
  median_fold: 23.0
  percent: 0.34
  priority: 1
- vaccine: BNT162b2
  dosage: 4.0
  infection: infected
  num_ref_name: 3
  num_fold: 268
  S: 40
  I: 126
  R: 102
  median_fold: 16.0
  percent: 0.18
  priority: 1
- vaccine: mRNA-1273
  dosage: 1.0
  infection: ''
  num_ref_name: 2
  num_fold: 155
  S: 131
  I: 24
  R: 0
  median_fold: 1.5
  percent: 0.11
  priority: 2
- vaccine: mRNA-1273
  dosage: 1.0
  infection: infected
  num_ref_name: 2
  num_fold: 14
  S: 7
  I: 4
  R: 3
  median_fold: 5.3
  percent: 0.0096
  priority: 2
- vaccine: mRNA-1273
  dosage: 2.0
  infection: ''
  num_ref_name: 68
  num_fold: 9358
  S: 6213
  I: 2586
  R: 559
  median_fold: 3.9
  percent: 6.4
  priority: 2
- vaccine: mRNA-1273
  dosage: 2.0
  infection: infected
  num_ref_name: 11
  num_fold: 447
  S: 307
  I: 114
  R: 26
  median_fold: 3.0
  percent: 0.31
  priority: 2
- vaccine: mRNA-1273
  dosage: 3.0
  infection: ''
  num_ref_name: 23
  num_fold: 4443
  S: 2909
  I: 1454
  R: 80
  median_fold: 4.5
  percent: 3.1
  priority: 2
- vaccine: mRNA-1273
  dosage: 3.0
  infection: infected
  num_ref_name: 7
  num_fold: 517
  S: 255
  I: 251
  R: 11
  median_fold: 5.1
  percent: 0.36
  priority: 2
- vaccine: mRNA-1273
  dosage: 4.0
  infection: ''
  num_ref_name: 3
  num_fold: 532
  S: 260
  I: 269
  R: 3
  median_fold: 12.0
  percent: 0.37
  priority: 2
- vaccine: mRNA-1273
  dosage: 4.0
  infection: infected
  num_ref_name: 2
  num_fold: 295
  S: 114
  I: 153
  R: 28
  median_fold: 5.5
  percent: 0.2
  priority: 2
- vaccine: Ad26.COV2.S
  dosage: 1.0
  infection: ''
  num_ref_name: 22
  num_fold: 1598
  S: 1097
  I: 416
  R: 85
  median_fold: 3.0
  percent: 1.1
  priority: 3
- vaccine: Ad26.COV2.S
  dosage: 1.0
  infection: infected
  num_ref_name: 8
  num_fold: 198
  S: 141
  I: 48
  R: 9
  median_fold: 2.6
  percent: 0.14
  priority: 3
- vaccine: Ad26.COV2.S
  dosage: 2.0
  infection: ''
  num_ref_name: 8
  num_fold: 558
  S: 289
  I: 253
  R: 16
  median_fold: 4.6
  percent: 0.38
  priority: 3
- vaccine: AZD1222
  dosage: 1.0
  infection: ''
  num_ref_name: 10
  num_fold: 1752
  S: 689
  I: 559
  R: 504
  median_fold: 6.0
  percent: 1.2
  priority: 4
- vaccine: AZD1222
  dosage: 1.0
  infection: infected
  num_ref_name: 4
  num_fold: 680
  S: 587
  I: 93
  R: 0
  median_fold: 3.3
  percent: 0.47
  priority: 4
- vaccine: AZD1222
  dosage: 2.0
  infection: ''
  num_ref_name: 40
  num_fold: 3676
  S: 1968
  I: 1076
  R: 632
  median_fold: 4.6
  percent: 2.5
  priority: 4
- vaccine: AZD1222
  dosage: 2.0
  infection: infected
  num_ref_name: 14
  num_fold: 1847
  S: 1212
  I: 519
  R: 116
  median_fold: 3.6
  percent: 1.3
  priority: 4
- vaccine: AZD1222
  dosage: 3.0
  infection: ''
  num_ref_name: 6
  num_fold: 990
  S: 211
  I: 779
  R: 0
  median_fold: 6.8
  percent: 0.68
  priority: 4
- vaccine: BBIBP-CorV
  dosage: 2.0
  infection: ''
  num_ref_name: 12
  num_fold: 3147
  S: 1933
  I: 879
  R: 335
  median_fold: 3.4
  percent: 2.2
  priority: 6
- vaccine: BBIBP-CorV
  dosage: 3.0
  infection: ''
  num_ref_name: 5
  num_fold: 552
  S: 113
  I: 438
  R: 1
  median_fold: 20.0
  percent: 0.38
  priority: 6
- vaccine: BBV152
  dosage: 2.0
  infection: ''
  num_ref_name: 7
  num_fold: 477
  S: 449
  I: 7
  R: 21
  median_fold: 1.4
  percent: 0.33
  priority: 7
- vaccine: BBV152
  dosage: 2.0
  infection: infected
  num_ref_name: 2
  num_fold: 170
  S: 151
  I: 0
  R: 19
  median_fold: 2.4
  percent: 0.12
  priority: 7
- vaccine: CoronaVac
  dosage: 1.0
  infection: ''
  num_ref_name: 3
  num_fold: 220
  S: 220
  I: 0
  R: 0
  median_fold: 1.5
  percent: 0.15
  priority: 8
- vaccine: CoronaVac
  dosage: 1.0
  infection: infected
  num_ref_name: 3
  num_fold: 390
  S: 242
  I: 148
  R: 0
  median_fold: 3.3
  percent: 0.27
  priority: 8
- vaccine: CoronaVac
  dosage: 2.0
  infection: ''
  num_ref_name: 21
  num_fold: 2376
  S: 1600
  I: 717
  R: 59
  median_fold: 3.1
  percent: 1.6
  priority: 8
- vaccine: CoronaVac
  dosage: 2.0
  infection: infected
  num_ref_name: 7
  num_fold: 250
  S: 136
  I: 74
  R: 40
  median_fold: 4.7
  percent: 0.17
  priority: 8
- vaccine: CoronaVac
  dosage: 3.0
  infection: ''
  num_ref_name: 17
  num_fold: 5275
  S: 1225
  I: 2954
  R: 1096
  median_fold: 9.8
  percent: 3.6
  priority: 8
- vaccine: CoronaVac
  dosage: 3.0
  infection: infected
  num_ref_name: 7
  num_fold: 11914
  S: 2519
  I: 5522
  R: 3873
  median_fold: 14.0
  percent: 8.2
  priority: 8
- vaccine: NVX-CoV2373
  dosage: 2.0
  infection: ''
  num_ref_name: 4
  num_fold: 275
  S: 110
  I: 103
  R: 62
  median_fold: 8.1
  percent: 0.19
  priority: 9
- vaccine: NVX-CoV2373
  dosage: 3.0
  infection: ''
  num_ref_name: 2
  num_fold: 212
  S: 48
  I: 164
  R: 0
  median_fold: 8.2
  percent: 0.15
  priority: 9
- vaccine: ZF2001
  dosage: 3.0
  infection: ''
  num_ref_name: 7
  num_fold: 716
  S: 210
  I: 461
  R: 45
  median_fold: 8.1
  percent: 0.49
  priority: 10
- vaccine: mRNA-1273 + mRNA-1273.211
  dosage: 3.0
  infection: ''
  num_ref_name: 3
  num_fold: 4882
  S: 4850
  I: 32
  R: 0
  median_fold: 2.3
  percent: 3.4
  priority: 24
- vaccine: BNT162b2 + mRNA-1273
  dosage: 3.0
  infection: ''
  num_ref_name: 5
  num_fold: 423
  S: 170
  I: 250
  R: 3
  median_fold: 7.4
  percent: 0.29
  priority: 34
- vaccine: BNT162b2 + mRNA-1273
  dosage: 3.0
  infection: infected
  num_ref_name: 7
  num_fold: 354
  S: 259
  I: 63
  R: 32
  median_fold: 3.0
  percent: 0.24
  priority: 34
- vaccine: BNT162b2 + mRNA-1273
  dosage: 4.0
  infection: ''
  num_ref_name: 3
  num_fold: 66
  S: 11
  I: 21
  R: 34
  median_fold: 32.0
  percent: 0.045
  priority: 34
- vaccine: BNT162b2 + BNT162b2_BA.4/5_bivalent
  dosage: 4.0
  infection: ''
  num_ref_name: 2
  num_fold: 141
  S: 36
  I: 57
  R: 48
  median_fold: 16.0
  percent: 0.097
  priority: 39
- vaccine: mRNA-monovalent
  dosage: 2.0
  infection: infected
  num_ref_name: 4
  num_fold: 114
  S: 51
  I: 45
  R: 18
  median_fold: 5.1
  percent: 0.078
  priority: 47
- vaccine: mRNA-monovalent
  dosage: 3.0
  infection: ''
  num_ref_name: 10
  num_fold: 970
  S: 200
  I: 401
  R: 369
  median_fold: 14.0
  percent: 0.67
  priority: 47
- vaccine: mRNA-monovalent
  dosage: 3.0
  infection: infected
  num_ref_name: 9
  num_fold: 1661
  S: 755
  I: 425
  R: 481
  median_fold: 6.0
  percent: 1.1
  priority: 47
- vaccine: mRNA-monovalent
  dosage: 4.0
  infection: ''
  num_ref_name: 3
  num_fold: 414
  S: 38
  I: 207
  R: 169
  median_fold: 15.0
  percent: 0.28
  priority: 47
- vaccine: mRNA-monovalent
  dosage: 4.0
  infection: infected
  num_ref_name: 2
  num_fold: 275
  S: 120
  I: 70
  R: 85
  median_fold: 9.4
  percent: 0.19
  priority: 47
- vaccine: mRNA-bivalent + mRNA-monovalent
  dosage: 3.0
  infection: ''
  num_ref_name: 3
  num_fold: 138
  S: 54
  I: 68
  R: 16
  median_fold: 6.9
  percent: 0.095
  priority: 48
- vaccine: mRNA-bivalent + mRNA-monovalent
  dosage: 3.0
  infection: infected
  num_ref_name: 2
  num_fold: 110
  S: 44
  I: 55
  R: 11
  median_fold: 8.0
  percent: 0.076
  priority: 48
- vaccine: mRNA-bivalent + mRNA-monovalent
  dosage: 4.0
  infection: ''
  num_ref_name: 8
  num_fold: 1874
  S: 228
  I: 1107
  R: 539
  median_fold: 11.0
  percent: 1.3
  priority: 48
- vaccine: mRNA-bivalent + mRNA-monovalent
  dosage: 4.0
  infection: infected
  num_ref_name: 4
  num_fold: 1091
  S: 311
  I: 667
  R: 113
  median_fold: 6.4
  percent: 0.75
  priority: 48
- vaccine: Convidecia
  dosage: 1.0
  infection: ''
  num_ref_name: 2
  num_fold: 215
  S: 215
  I: 0
  R: 0
  median_fold: 1.4
  percent: 0.15
  priority: 50
- vaccine: Sputnik V
  dosage: 2.0
  infection: ''
  num_ref_name: 8
  num_fold: 592
  S: 408
  I: 142
  R: 42
  median_fold: 4.0
  percent: 0.41
  priority: 52
- vaccine: AZD1222 + Sputnik V
  dosage: 3.0
  infection: ''
  num_ref_name: 2
  num_fold: 104
  S: 28
  I: 76
  R: 0
  median_fold: 9.5
  percent: 0.072
  priority: 54
- vaccine: KCONVAC
  dosage: 3.0
  infection: ''
  num_ref_name: 2
  num_fold: 251
  S: 241
  I: 10
  R: 0
  median_fold: 1.2
  percent: 0.17
  priority: 56
- vaccine: CoronaVac or BBIBP-CorV
  dosage: 3.0
  infection: ''
  num_ref_name: 2
  num_fold: 588
  S: 541
  I: 47
  R: 0
  median_fold: 4.2
  percent: 0.4
  priority: 57
- vaccine: Ad26.COV2.S + BNT162b2
  dosage: 2.0
  infection: ''
  num_ref_name: 3
  num_fold: 225
  S: 98
  I: 107
  R: 20
  median_fold: 7.5
  percent: 0.15
  priority: 64
- vaccine: Ad26.COV2.S + BNT162b2
  dosage: 2.0
  infection: infected
  num_ref_name: 2
  num_fold: 6
  S: 6
  I: 0
  R: 0
  median_fold: 0.65
  percent: 0.0041
  priority: 64
- vaccine: Ad26.COV2.S + BNT162b2
  dosage: 3.0
  infection: ''
  num_ref_name: 4
  num_fold: 552
  S: 425
  I: 127
  R: 0
  median_fold: 2.6
  percent: 0.38
  priority: 64
- vaccine: Ad26.COV2.S + mRNA-1273
  dosage: 2.0
  infection: ''
  num_ref_name: 2
  num_fold: 270
  S: 135
  I: 135
  R: 0
  median_fold: 5.4
  percent: 0.19
  priority: 65
- vaccine: AZD1222 + BNT162b2
  dosage: 2.0
  infection: ''
  num_ref_name: 12
  num_fold: 1862
  S: 544
  I: 468
  R: 850
  median_fold: 12.0
  percent: 1.3
  priority: 68
- vaccine: AZD1222 + BNT162b2
  dosage: 2.0
  infection: infected
  num_ref_name: 2
  num_fold: 12
  S: 6
  I: 5
  R: 1
  median_fold: 4.9
  percent: 0.0083
  priority: 68
- vaccine: AZD1222 + BNT162b2
  dosage: 3.0
  infection: ''
  num_ref_name: 9
  num_fold: 1187
  S: 459
  I: 482
  R: 246
  median_fold: 7.9
  percent: 0.82
  priority: 68
- vaccine: AZD1222 + BNT162b2 + CoronaVac
  dosage: 3.0
  infection: ''
  num_ref_name: 2
  num_fold: 89
  S: 89
  I: 0
  R: 0
  median_fold: 2.6
  percent: 0.061
  priority: 69
- vaccine: AZD1222 + CoronaVac
  dosage: 2.0
  infection: ''
  num_ref_name: 2
  num_fold: 209
  S: 120
  I: 29
  R: 60
  median_fold: 3.3
  percent: 0.14
  priority: 70
- vaccine: AZD1222 + CoronaVac
  dosage: 3.0
  infection: ''
  num_ref_name: 4
  num_fold: 875
  S: 698
  I: 167
  R: 10
  median_fold: 2.6
  percent: 0.6
  priority: 70
- vaccine: AZD1222 + mRNA-1273
  dosage: 2.0
  infection: ''
  num_ref_name: 3
  num_fold: 268
  S: 187
  I: 63
  R: 18
  median_fold: 4.5
  percent: 0.18
  priority: 73
- vaccine: AZD1222 + mRNA-1273
  dosage: 3.0
  infection: ''
  num_ref_name: 2
  num_fold: 680
  S: 560
  I: 120
  R: 0
  median_fold: 1.8
  percent: 0.47
  priority: 73
- vaccine: BBIBP-CorV + BNT162b2
  dosage: 3.0
  infection: ''
  num_ref_name: 2
  num_fold: 149
  S: 113
  I: 36
  R: 0
  median_fold: 3.5
  percent: 0.1
  priority: 76
- vaccine: BBIBP-CorV + ZF2001
  dosage: 3.0
  infection: ''
  num_ref_name: 4
  num_fold: 252
  S: 52
  I: 182
  R: 18
  median_fold: 7.8
  percent: 0.17
  priority: 78
- vaccine: BNT162b2 + CoronaVac
  dosage: 3.0
  infection: ''
  num_ref_name: 12
  num_fold: 1398
  S: 978
  I: 405
  R: 15
  median_fold: 2.6
  percent: 0.96
  priority: 80
- vaccine: BNT162b2 + CoronaVac
  dosage: 3.0
  infection: infected
  num_ref_name: 3
  num_fold: 324
  S: 244
  I: 76
  R: 4
  median_fold: 2.0
  percent: 0.22
  priority: 80
- vaccine: CoronaVac + ZF2001
  dosage: 3.0
  infection: ''
  num_ref_name: 2
  num_fold: 469
  S: 228
  I: 164
  R: 77
  median_fold: 6.4
  percent: 0.32
  priority: 87
- vaccine: CoronaVac + mRNA-1273
  dosage: 3.0
  infection: ''
  num_ref_name: 2
  num_fold: 98
  S: 98
  I: 0
  R: 0
  median_fold: 4.2
  percent: 0.067
  priority: 88
- vaccine: BNT162b2 or AZD1222 + mRNA-monovalent
  dosage: 4.0
  infection: ''
  num_ref_name: 2
  num_fold: 60
  S: 0
  I: 30
  R: 30
  median_fold: 31.0
  percent: 0.041
  priority: 95
- vaccine: mRNA-bivalent + Unknown vaccine
  dosage: 4.0
  infection: ''
  num_ref_name: 2
  num_fold: 72
  S: 23
  I: 13
  R: 36
  median_fold: 34.0
  percent: 0.05
  priority: 96
- vaccine: Unknown vaccine
  dosage: 1.0
  infection: infected
  num_ref_name: 3
  num_fold: 244
  S: 116
  I: 107
  R: 21
  median_fold: 6.7
  percent: 0.17
  priority: 98
- vaccine: Unknown vaccine
  dosage: 2.0
  infection: ''
  num_ref_name: 2
  num_fold: 528
  S: 320
  I: 177
  R: 31
  median_fold: 3.2
  percent: 0.36
  priority: 98
- vaccine: Unknown vaccine
  dosage: 2.0
  infection: infected
  num_ref_name: 11
  num_fold: 1039
  S: 839
  I: 136
  R: 64
  median_fold: 2.2
  percent: 0.71
  priority: 98
- vaccine: Unknown vaccine
  dosage: 3.0
  infection: ''
  num_ref_name: 2
  num_fold: 78
  S: 32
  I: 43
  R: 3
  median_fold: 7.2
  percent: 0.054
  priority: 98
- vaccine: Unknown vaccine
  dosage: 3.0
  infection: infected
  num_ref_name: 11
  num_fold: 1003
  S: 702
  I: 237
  R: 64
  median_fold: 2.8
  percent: 0.69
  priority: 98
